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A great number of diseases are directly related to active smoking. In the resent 
years more and more malignant neoplasms were causally related to active smoking.1 
Lung cancer is the “leader” of smoking related neoplasm’s and the 3rd cause of death 
in high income countries,2 followed by cancer of the oral cavity/pharynx, laryngeal, 
esophageal, stomach, pancreatic, kidney, bladder, cervical cancer, leukemia and other 
malignant neoplasm’s. Among other diseases, cardiovascular (coronary heart disease, 
peripheral vascular disease cerebrovascular disease and abdominal aortic aneurysm) 
and respiratory diseases (chronic obstructive pulmonary disease-COPD, pneumonia) 
are also causally related to cigarette smoking. According to World Health Organiza-
tion (WHO) 5 out of 6 leading causes of death world wide (Ischemic heart disease, 
cerebrovascular disease, HIV/AIDS, COPD, lower respiratory infections trachea, bron-
chus, lung cancers) are smoke related. WHO claims that under the baseline scenario, 
total tobacco-attributable deaths will rise from 5.4 million in 2005 to 6.4 million in 
2015 and 8.3 million in 2030. Projected deaths for 2030 range from 7.4 million in 
the optimistic scenario to 9.7 million in the pessimistic scenario. According to their 
baseline projection, smoking will kill 50% more people in 2015 than HIV/AIDS, and 
will be responsible for 10% of all deaths globally2.
S M O K I N G  A N D  C A R D I O V A S C U L A R  D I S E A S E
Cardiovascular diseases are the first cause of death independently of income state 
and existing evidence is more than sufficient to establish a causal relationship between 
each of them and cigarette smoking1.
S M O K I N G  A N D  C O R O N A R Y  A R T E R Y  D I S E A S E  ( C A D )
The role of smoking in ischemic heart disease includes endothelial dysfunction, 
increased hematologic thrombogenicity, enhanced inflammatory response and oxida-
tive modification.3 Tissue factor (TF) is highly expressed in atherosclerotic plaques 
and may play a role in thrombosis. Current smokers have significantly higher levels 
of circulating TF activity than nonsmokers4. Smoking impairs endothelial vasodila-
tor function since flow-dependent dilation is significantly blunted in current smok-
ers compared with nonsmokers and long-term cigarette smoking is associated with 
impaired endothelium-dependent coronary vasodilatation regardless of the presence 
or absence of coronary atherosclerotic lesions.5
Young smokers are characterized by epicardial coronary endothelial dysfunction, 
elevated white blood cell (WBC) counts and increased levels of inflammatory biomark-
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ers and oxidative stress6. Elevated WBC counts are associated 
with greater coronary heart disease mortality7. Smoking leads 
to increased oxidative modification of important biologic 
molecules in vivo8 and reduces nitric oxide (NO) biosynthesis9. 
It’s no wonder that smoking increases CAD mortality10 and 
rate of progression11, multiplies risk factor for CAD along 
with hypertension and hypercholesterolemia12, increases the 
risk of angina13, of sudden cardiac death14, of acute nonfatal 
myocardial infraction (MI)15 and of Q-wave MI after percu-
taneous coronary revascularization16.
In summary:
Smoking plays a role in the development of CAD via:
– Endothelial dysfunction
– Increased thrombogenicity
– Elevated WBC counts
– Increased oxidative stress
– Reduced NO biosynthesis
Smoking acts as a multiplicative risk factor for develop-
ment of CAD
Smoking is associated with an increased
– Rate of progression of CAD
– Risk of angina
– Risk of acute myocardial infarction
– Risk of sudden cardiac death
– Risk of Q-wave myocardial infarction after percutane-
ous coronary revascularization.
S M O K I N G  A N D  P E R I P H E R A L  VA S C U L A R 
D I S E A S E  ( P V D ) :
PVD affects approximately 20% of adults older than age 
5517. Approximately half of patients with PVD are asympto-
matic18 and 5% to 10% of them will progress to symptomatic 
PVD over 5 years19. Patients with symptomatic PVD are at 
higher risk for other cardiovascular disease and mortality20. 
Current smokers develop asymptomatic PVD 2,8 times more 
often than nonsmokers and ex-smokers 1,6 times respectively.20 
The rate of development of intermittent claudication (IC) is 
approximately 4 times as great in current smokers as in non-
smokers (OR 4.1[2.3-7.9]) and risk tends to increase with the 
intensity of smoking. The 5-year mortality for patients with 
IC who continue to smoke is 40% to 50%20,21. For smokers, 
the risk of PVD is greater than the risk of CAD.22 Smoking is 
the most important risk factor for the progression PVD and 
symptoms occur approximately a decade earlier in smokers 
than nonsmokers while smokers with PVD have twice the 
amputation rate of nonsmokers23. Continued smoking after 
lower limb bypass surgery results in a threefold increased risk 
of graft failure. Smoking cessation, even if instigated after the 
operation, restores graft patency towards the patency of never 
smokers.24 Smoking is also associated with increased mortality 
after vascular surgery.25
•
•
•
In summary:
Smoking is associated with an increased risk of
– Asymptomatic PVD
– Intermittent claudication
– Progression of PVD
– Amputation due to complications of PVD
– Femoral-popliteal bypass graft failure
– Mortality after vascular surgery
Symptoms of PVD occur approximately a decade earlier 
in smokers than in nonsmokers
Current smokers are at greater risk for developing PVD 
than coronary artery disease.
S M O K I N G  A N D  A B D O M I N A L  A O R T I C  A N E U R Y S M 
( A A A )
The association between smoking and aortic aneurysm is 
substantially stronger than the association between smoking 
and coronary or cerebrovascular disease. Current smokers 
develop AAA 3 times more often than CAD and 4,7 times than 
cerebrovascular disease26. Smoking is an independent and re-
mains the most important avoidable risk factor for AAA, with 
level of exposure (cigarettes/day) being more significant than 
duration27. In fact the progression of aortic atherosclerosis is 
directly associated to the number of cigarettes smoked per 
day28. Smoking also accelerates AAA expansion while other 
factors including lipids and blood pressure are not associated 
with AAA growth29. 
In conclusion:
Current smokers have a higher risk of developing an AAA 
than either coronary artery disease or cerebrovascular 
disease
Smoking is associated with an increased risk of
– Formation of AAA
– Progression of aortic atherosclerosis
– Expansion of AAA
S M O K I N G  A N D  S T R O K E : 
Smoking contributes to 12% to 14% of all stroke deaths. 
Smoking also potentiates the effects of other stroke risk fac-
tors and increases stroke risk acutely, effecting the thrombus 
formation and chronically, increasing the burden of athero-
sclerotic disease30. Both active smoking and environmental 
tobacco smoke exposure are associated with increased pro-
gression of carotid atherosclerosis31. The number of cigarettes 
smoked per day is associated positively with the risk of stroke 
in women. Compared with the women who had never smoked, 
those who smoked 1 to 14 cigarettes per day had an age-ad-
justed relative risk of 2.2 (95 percent confidence interval, 1.5 
to 3.3), whereas those who smoked 25 or more cigarettes per 
day had a relative risk of 3.7 (95 percent confidence interval, 
2.7 to 5.1). For women in this latter group, the relative risk of 
subarachnoid haemorrhage was 9.8 (95 percent confidence 
•
•
•
•
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interval, 5.3 to 17.9), as compared with those who had never 
smoked32. Cigarette smoking increases the risk of total hemor-
rhagic stroke in women (both intracerebral and subarachnoid) 
and this is also positively associated with the amount of ciga-
rettes smoked per day33. Smoking also increases the mortality 
rate from stroke in men34. 
In conclusion:
Smoking contributes to 12% to 14% of all stroke deaths
Increases the risk of
– Progression of carotid atherosclerosis
– Ischemic stroke
– Hemorrhagic stroke
– Intracerebral hemorrhage
– Subarachnoid hemorrhage
Increases stroke-related mortality.
C A R D I O VA S C U L A R  D I S E A S E  
A N D  E N V I R O N M E N T A L  T O B A C C O  S M O K E
Environmental tobacco smoke effects cardiovascular 
system in several ways. Environmental tobacco smoke 
increases the risk of heart disease among non smokers by 
30%35, increases arterial stiffness, oxidative stress, inflamma-
tion, atherosclerosis and infract size while changing platelet 
and endothelial function, heart rate variability and energy 
metabolism36. Passive smoking may activate thromboxane A
2
 
release from the platelets, contributing to the development 
of hemostatic imbalance37, and significantly reduces mean 
coronary flow velocity reserve in nonsmokers thus causing 
endothelial dysfunction of the coronary circulation38. Expo-
sure to environmental tobacco smoke increases the risk of 
non-fatal acute myocardial infraction in a graded manner15. 
A public ordinance reducing exposure to second hand smoke 
in Pueblo city, Colorado, was associated with a decrease in 
acute myocardial infraction hospitalizations39.
In conclusion:
Exposure to environmental tobacco smoke increases 
risk of
– Heart disease, by 30%
– Acute myocardial infarction (MI)
Environmental tobacco smoke affects multiple factors as-
sociated with the development of coronary artery disease, 
including
– Platelet activation
– Vascular endothelial dysfunction.
C A R D I O V A S C U L A R  B E N E F I T S  
O F  S M O K I N G  C E S S A T I O N
The benefits of non-smoking and smoking cessation in 
healthy individuals and cardiac patients are beyond contro-
versy40. Abstention from smoking for a period of only 2 weeks 
•
•
•
•
•
induces a significant decrease in the rate of fibrinogen syn-
thesis by the liver, with a concomitant reduction in the plasma 
fibrinogen concentration41, while 8 weeks of smoking reduction 
results in clinically significant improvements in established 
cardiovascular risk factors (including fibrinogen, white blood 
cell count and the high-density/low-density lipoprotein-HDL/
LDL ratio). These improvements are even greater after an 
additional period of abstinence from smoking42. Smoking 
cessation also improves arterial stiffness as assessed by the 
augmentation index, owing mainly to increasing the small 
artery compliance, which is known to be an early index of 
endothelial damage43. Quitting smoke leads to a decreased 
platelet volume and increased susceptibility of platelets to 
antiaggregatory prostaglandin E144, while only two weeks 
of smoking cessation can ameliorate the enhanced platelet 
aggregability and intraplatelet redox imbalance in long-term 
smokers, possibly by decreasing oxidative stress45. Cessation 
of cigarette smoking is associated with a reduction in ar-
rhythmic death for patients with post-myocardial infarction 
and left ventricular dysfunction46 and a reduced risk of acute 
myocardial infraction15, while the risk for recurrent cardiac 
arrest is lower among those who quit smoking than among 
continuing smokers47. Patients who continue to smoke after 
a successful percutaneous coronary revascularization are 
at greater risk for Q-wave infarction and death than smoke 
quitters, so the cessation of smoking either before or after 
percutaneous revascularization is beneficial16. Patients who 
continue to smoke after coronary artery bypass graft surgery 
have a greater risk of death than those who stop smoking and 
also they undergo repeat revascularization procedures more 
frequently48. Smoke cessation also lowers the risk of PVD49 
and stroke50.
In conclusion the cardiovascular benefits of smoking ces-
sation can be divided into:
L O N G -T E R M  B E N E F I T S
Reduced risk of
– Stroke
– Repeat CABG
– Recurrent coronary events after MI
– Arrhythmic death after MI
– Secondary CVD events
– Revascularization procedure after CABG
Reduced
– Mortality after CABG
– Mortality after PTCA
– Levels of inflammatory markers associated with 
progression of CVD (C-reactive protein, WBC, and 
fibrinogen)
S H O R T-T E R M  B E N E F I T S
 fibrinogen concentration
 rate of fibrinogen synthesis
•
•
•
•
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 WBCs
Improved HDL/LDL ratio
 risk of stroke
 HDL; decreased LDL
 arterial pressure
 HR
Improved arterial compliance
 risk of arrhythmic death after MI
 platelet volume
Enhanced platelet cAMP response to stimulation of ADP 
with prostaglandin E1
 smoking-induced platelet aggregability.
D E P R E S S I O N ,  S M O K I N G  A N D 
C A R D I O V A S C U L A R  D I S E A S E
Smokers with psychiatric disorders consume more 
cigarettes. Namely the Odds Ratio for smokers and major 
depression is 3.2. Also psychiatric patients who smoke 
have:
 - Higher incidence of illicit drug use.
 - Poorer treatment compliance
 - Lower Global Assessment Functioning (GAF) score
The relationship between cardiovascular disease and depres-
sion poses a lot of interesting questions. Preliminary studies have 
shown the following:
Depression increases the risk of coronary artery disease 
by 1.5 – 2 times in otherwise physically healthy individu-
als.51
Patients with early-onset depression are at a significantly 
increased risk for developing cardiovascular disease 
(CVD) after correcting for cardiovascular risk factors. 
This effect occurs even in the absence of a diagnosis of 
major depression.52
Patients with treatment-resistant depression (failure to 
respond to a single trial of antidepressant) after an acute 
coronary syndrome are at even greater cardiovascular 
risk.53
Patients with CVD such as myocardial infarction, stroke, 
heart failure, and atrial fibrillation are at increased risk 
of developing depression and, when depression develops, 
cardiovascular risk is exacerbated further.51,54
As for the use of drugs research has shown that:
The use of antidepressants does not appear to mitigate 
cardiovascular risk associated with depression, despite 
altering one or more of the physiological abnormalities 
linking CVD to depression such as increased inflam-
matory cytokines, a decreased circulation of endothelial 
progenitor cells,
and a deficiency in nitric oxide availability.55-57
The combination of an SSRI and n-3 fatty acids reduce 
mood-associated cardiovascular risk.58
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
In patients surviving their first hospitalization for heart 
failure the use of both TCAs and SSRIs is associated 
with an increased risk of total and cardiovascular-related 
mortality.59
Co-administration of an SSRI and a beta-adrenergic block-
ing agent is associated with an increased risk of total and 
cardiovascular-related mortality.
Further clinical study needs to be done in order to deter-
mine the optimum antidepressant strategy in patients with heart 
failure.
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